Scyllo-Inositol: Difference between revisions

| verifiedrevid = 428259682

| ImageSize = 200px

| IUPACName = (1''R'',2''R'',3''R'',4''R'',5''R'',6''R'')-Cyclohexane-1,2,3,4,5,6-hexaol

| Section1 = {{Chembox Identifiers

| Section2 = {{Chembox Properties

| C=6|H=12|O=6

| MeltingPt = 348.5-350 °C

| Section3 = {{Chembox Hazards

| Autoignition = }}

'''''scyllo''-Inositol''' is one of the [[stereoisomer]]s of [[inositol]]. It is also known as scyllitol, cocositol, quercinitol, and 1,3,5/2,4,6-hexahydroxycyclohexane. ''scyllo''-Inositol is a naturally occurring plant sugar [[alcohol]] found most abundantly in the [[coconut palm]].<ref>[http://www.ars-grin.gov/cgi-bin/duke/chemical.pl?SCYLLITOL Scyllitol], Dr. Duke's Phytochemical and Ethnobotanical Databases</ref>

Researchers at the [[University of Toronto]] have found that ''scyllo''-inositol can block the development of [[amyloid-beta]] (Aβ) plaques in the brains of transgenic mice.<ref>[http://www.alzforum.org/new/detail.asp?id=1414 Aβ Busters and Other Ploys Show Promise for Treating Neurodegeneration]</ref> ''scyllo''-Inositol also reversed memory deficits, reduced the formation of Aβ [[Senile plaques|plaques]], and alleviated other symptoms that are associated with the accumulation of Aβ proteins in these mice.<ref>{{cite journal | pmid = 16767098 | doi=10.1038/nm1423 | volume=12 | issue=7 | title=Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model | year=2006 | month=July | pages=801–8}}</ref>

''scyllo''-Inositol is under investigation by [[Transition Therapeutics]] as a disease-modifying therapy for [[Alzheimer's disease]] under the designation AZD-103. A patent was issued on April 21, 2009 (US patent number 7,521,481) claiming the use of ''scyllo''-inositol for treating Alzheimer's disease.<ref>[http://newsroom.elan.com/phoenix.zhtml?c=88326&p=irol-newsArticle&ID=1279660&highlight=ELND005 Elan and Transition Therapeutics Receive Key Patent for Alzheimer's Disease Treatment with ELND005]</ref> ''scyllo''-Inositol is undergoing clinical investigation as an orally-administered therapeutic agent for the treatment of mild to moderate Alzheimer's disease. It has received [[FDA Fast Track Development Program|fast track designation]] from the [[U.S. Food and Drug Administration]]. Transition has partnered with [[Elan Corporation]] on the development of the compound under the designation ELND005. ELND005 is currently in a Phase 2 clinical study, which completed enrollment in October 2008. The study is a randomized, double-blind, placebo-controlled, dose-ranging, safety and efficacy study in approximately 353 patients with mild to moderate Alzheimer's disease. The planned treatment period for each patient is approximately 18 months.

In December 2009, Elan and Transition jointly reported that the study has been modified so that only the 250 mg twice daily dose will be continued because of greater rates of adverse events, including 9 deaths, in the higher dose groups (1000 mg and 2000 mg dosed twice daily).<ref>[http://finance.yahoo.com/news/Elan-and-Transition-bw-2610034367.html?x=0&.v=1 Elan and Transition Therapeutics Announce Modifications to ELND005 Phase II Clinical Trials in Alzheimer's Disease]</ref>

== External Links ==

[http://www.alzforum.org/drg/drc/detail.asp?id=130 Drugs In Clinical Trials - ELND005]

[[Category:inositol]]